How Novartis slashed turnaround time for managed access

In the early days of the pandemic, Novartis faced a rapid influx of managed access and compassionate use requests for COVID-19 treatments. To support the large volume of applications, the team quickly realized they needed to accelerate their existing workflows to expedite drug delivery for patients in need. In partnership with Bonterra, Novartis identified and eliminated bottlenecks within the review and approval process, reducing managed access turnaround time from five days to five hours.